title: Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability.
abstract: Red blood cell (RBC) aggregation may contribute to occlusion of the coronary microcirculation during myocardial infarction. We studied the effect of thrombolytic therapy on RBC aggregation in patients with acute myocardial infarction (AMI). Compared with patients with myocardial infarction who did not receive thrombolytic therapy, those treated with systemic thrombolysis exhibited significantly reduced RBC aggregation, reduced plasma fibrinogen levels and increased plasma D-dimer levels. Using measurement of RBC aggregation in a standardized dextran-500 solution, reduction in RBC aggregation after thrombolysis was shown to be plasma dependent. Thrombolytic therapy had no direct effect on intrinsic RBC aggregability in patients with AMI. We conclude that thrombolytic therapy has rheologic consequences that may contribute to its overall efficacy. Inhibition of RBC aggregation by thrombolytic therapy may result from the degradation of fibrinogen, a key factor in the formation of RBC aggregates, and from the generation of fibrinogen degradation products capable of disaggregating RBCs.
authors.affiliation: Department of Internal Medicine, Sourasky Medical Center, Tel-Aviv 64239, Israel. rbenami1@zahav.net.il
authors.forename: R
authors.initials: R
authors.lastname: Ben-Ami
authors.forename: G
authors.initials: G
authors.lastname: Sheinman
authors.forename: S
authors.initials: S
authors.lastname: Yedgar
authors.forename: A
authors.initials: A
authors.lastname: Eldor
authors.forename: A
authors.initials: A
authors.lastname: Roth
authors.forename: A S
authors.initials: AS
authors.lastname: Berliner
authors.forename: G
authors.initials: G
authors.lastname: Barshtein
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D003911:Dextrans / Q000494:pharmacology; D004903:Erythrocyte Aggregation / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D010949:Plasma; D013300:Streptokinase / Q000008:administration & dosage; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D003911:Dextrans; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005340:Fibrinogen; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D001241:Aspirin